Antitumor effect of liposome incorporating mycolic acid of Mycobacterium bovis bacillus Calmette-Guérin in mouse model.
Project/Area Number |
26462397
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Urology
|
Research Institution | University of Tsukuba |
Principal Investigator |
MIYAZAKI Jun 筑波大学, 医学医療系, 准教授 (10550246)
|
Co-Investigator(Kenkyū-buntansha) |
西山 博之 筑波大学, 医学医療系, 教授 (20324642)
高岡 栄一郎 筑波大学, 医学医療系, 講師 (50625340)
河合 弘二 筑波大学, 医学医療系, 講師 (90272195)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | 膀胱癌 / ビーシージー / ミコール酸 / 癌免疫 / 感染免疫 / 脂質免疫 / 抗酸菌 / 脂質 / BCG / リポソーム / 細胞壁成分 |
Outline of Final Research Achievements |
Introduction and Objectives. Intravesical instillation of live bacillus Calmette-Guerin (BCG) is established immuno therapy of non-muscle invasive bladder cancer. Mycolic acids (MA) are the dominant lipids found in the cell wall of Mycobacterium species. We developed novel liposome incorporating MA and examined antitumor effects of MA. Methods. MA was isolated from M. bovis BCG Tokyo, and separated into three subclasses (alpha, methoxy and keto). Liposomes are prepared by sonication and extrusion. C57BL/6 mice were subcutaneously inoculated with a mixture of MB49 cells and PBS or liposome with/without MA followed by additional injection of PBS or liposome. Tumor growth was monitored. Results. Tumor growth was significantly suppressed in mice treated with Keto MA-liposome (p=0.007 vs PBS). Conclusion. Keto MA-liposome showed antitumor effects in mouse.
|
Report
(4 results)
Research Products
(2 results)
-
[Journal Article] Impact of renal function of patients with advanced urothelial cancer on eligibility for first-line chemotherapy and treatment outcomes.2015
Author(s)
9.Ichioka D, Miyazaki J, Inoue T, Kageyama S, Sugimoto M, Mitsuzuka K, Matsui Y, Shiraishi Y, Kinoshita H, Wakeda H, Nomoto T, Kikuchi E, Nishiyama H.
-
Journal Title
Jpn J Clin Oncol.
Volume: 45(9)
Issue: 9
Pages: 867-73
DOI
Related Report
Peer Reviewed / Acknowledgement Compliant
-